рджрд┐рди рдореЗрдВ рддреЗрдЬ, рд╕реНрдкрд╖реНрдЯ рджреГрд╖реНрдЯрд┐...

тАжрдЬреЛ рд░рд╛рдд рдореЗрдВ рдмрдврд╝рддреА рд╣реИред рдпрд╣ рд╕рдВрднрд╡ рд╣реИред

ICL рдХреЗ рд╕рд╛рде рдЙрддреНрдХреГрд╖реНрдЯ рд░рд╛рддреНрд░рд┐ рджреГрд╖реНрдЯрд┐ рд╣рд╛рд╕рд┐рд▓ рдХрд░реЗрдВред

рдЬреАрд╡рди рдХреЗ рд╕рднреА рдЫреЛрдЯреЗ-рдЫреЛрдЯреЗ рд▓рдореНрд╣реЛрдВ рдХреЗ рд▓рд┐рдП

рдЕрдкрдиреА рд░рд╛рдд рдХреА рджреГрд╖реНрдЯрд┐ рд╕реЗ рд╕рдордЭреМрддрд╛ рдХрд┐рдП рдмрд┐рдирд╛ рдЕрдкрдиреЗ рджрд┐рди рдФрд░ рд░рд╛рдд рдХреЗ рд╣рд░ рдПрдХ рдорд┐рдирдЯ рдореЗрдВ рдЬреАрд╡рди рдЖрдкрдХреЛ рдЬреЛ рджреЗрддрд╛ рд╣реИ рдЙрд╕рд╕реЗ рдЕрдзрд┐рдХ рдХрд╛ рдЕрдиреБрднрд╡ рдХрд░реЗрдВред

рди рдХреЗрд╡рд▓ рд░рд╛рдд рдХреЗ рд╕рдордп, рдмрд▓реНрдХрд┐ рдирд┐рдХрдЯ-рджреГрд╖реНрдЯрд┐рджреЛрд╖ рдХреЗ рд▓рд┐рдП рднреА

рджреВрд░ рд╕реЗ рднреА рдЕрдкрдиреА рдордирдкрд╕рдВрдж рдлрд┐рд▓реНрдореЗрдВ рдФрд░ рд╢реЛрдЬрд╝ рджреЗрдЦреЗрдВред ICL рдирд┐рдХрдЯ-рджреГрд╖реНрдЯрд┐рджреЛрд╖ (рдорд╛рдпреЛрдкрд┐рдпрд╛) рдХреЛ рдареАрдХ рдХрд░рддрд╛ рд╣реИ рдФрд░ рдХрдо рдХрд░рддрд╛ рд╣реИ рддрд╛рдХрд┐ рдЖрдк рдФрд░ рднреА рдЕрдзрд┐рдХ рдЖрдирдВрдж рд▓реЗрдиреЗ рдХреЗ рд▓рд┐рдП рд╕реНрд╡рддрдВрддреНрд░ рд╣реЛрдВред

рдЗрд╕рдореЗрдВ рдХреЗрд╡рд▓ 30 рдорд┐рдирдЯ рд▓рдЧрддреЗ рд╣реИрдВ

ICL рдкреНрд░рдХреНрд░рд┐рдпрд╛ рдиреНрдпреВрдирддрдо рдЗрдирд╡реЗрд╕рд┐рд╡ рд╣реИ рдФрд░ рд▓реЗрдВрд╕ рдХреЛ рдПрдХ рдЫреЛрдЯреЗ рд╕реЗ рдЪреАрд░реЗ рдХреЗ рдорд╛рдзреНрдпрдо рд╕реЗ рдЗрдореНрдкреНрд▓рд╛рдВрдЯ рдХрд┐рдпрд╛ рдЬрд╛рддрд╛ рд╣реИ рдЬрд┐рд╕рд╕реЗ рдкреНрд░рдХреНрд░рд┐рдпрд╛ рдФрд░ рд░рд┐рдХрд╡рд░реА рддреЗрдЬрд╝реА рд╕реЗ рд╣реЛрддреА рд╣реИред рджреБрдирд┐рдпрд╛ рднрд░ рдореЗрдВ рд▓рдЧрд╛рдП рдЧрдП 3,000,000 рд╕реЗ рдЕрдзрд┐рдХ рд▓реЗрдВрд╕реЛрдВ рдХреЗ рд╕рд╛рде, ICL рджреБрдирд┐рдпрд╛ рднрд░ рдореЗрдВ рдХрдИ рд▓реЛрдЧреЛрдВ рдХреЗ рд▓рд┐рдП рдкрд╕рдВрдж рдХреА рддреЗрдЬрд╝ рджреГрд╖реНрдЯрд┐ рд╕реБрдзрд╛рд░ рдкреНрд░рдХреНрд░рд┐рдпрд╛ рдмрди рд░рд╣рд╛ рд╣реИред

рдкреНрд░рдХреНрд░рд┐рдпрд╛ рдХреЗ рдмрд╛рд░реЗ рдореЗрдВ

Important Safety Information

EVO & EVO TICL is designed for the correction of moderate to high near-sightedness (-0.5 to -20.0 dioptres (D)) and the reduction of near-sightedness in patients with up to -20 dioptres (D) of near-sightedness with less than or equal to 6.0 dioptres (D) of astigmatism. It is indicated for patients who are 21 to 45 years of age. In order to be sure that your surgeon will use a EVO with the most adequate power for your eye, your near-sightedness should be stable for at least a year before undergoing eye surgery. EVO surgery has been documented to safely and effectively correct near-sightedness between -0.5 dioptres (D) to -20.0 dioptres (D) and partially correct near-sightedness up to -20 dioptres in eyes with up to 6.0(D) of astigmatism. If you have near-sightedness within these ranges, EVO surgery may improve your distance vision without eyeglasses or contact lenses. EVO surgery does not eliminate the need for reading glasses, even if you have never worn them before. The EVO represents an alternative to other refractive surgeries including, laser assisted in situ keratomileusis (LASIK), photorefractive keratectomy (PRK), incisional surgeries, or other means to correct myopia such as contact lenses and eye glasses. EVO is not intended to correct any astigmatism you may have. Implantation of the EVO is a surgical procedure, and as such, carries potentially serious risks. Please discuss the risks with your eye care provider. The following represent potential complications/adverse events reported in conjunction with refractive surgery in general: conjunctival irritation, acute corneal swelling, persistent corneal swelling, endophthalmitis (total eye infection), significant glare and/or halos around lights, hyphaema (blood in the eye), hypopyon (pus in the eye), eye infection, EVO ICL dislocation, macular oedema, non-reactive pupil, pupillary block glaucoma, severe inflammation of the eye, iritis, uveitis, vitreous loss and corneal transplant. Before considering EVO surgery you should have a complete eye examination and talk with your eye care professional about EVO surgery, especially the potential benefits, risks and complications. You should discuss the time needed for healing after surgery.

рд╕рдВрджрд░реНрдн

1Visian ICL Patient Information Booklet

2Sanders D. Vukich JA. Comparison of implantable collamer lens (ICL) and laser-assisted in situ keratomileusis (LASIK) for Low Myopia. Cornea. 2006 Dec; 25(10):1139-46.

3Naves, J.S. Carracedo, G. Cacho-Babillo, I. Diadenosine Nucleotid Measurements as Dry-Eye Score in Patients After LASIK and ICL Surgery. Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2012.

4Shoja, MR. Besharati, MR. Dry eye after LASIK for myopia: Incidence and risk factors. European Journal of Ophthalmology. 2007; 17(1): pp. 1-6.

5aLee, Jae Bum et al. Comparison of tear secretion and tear film instability after photorefractive keratectomy and laser in situ keratomileusis. Journal of Cataract & Refractive Surgery , Volume 26 , Issue 9 , 1326 - 1331.

5bParkhurst, G. Psolka, M. Kezirian, G. Phakic intraocular lens implantantion in United States military warfighters: A retrospective analysis of early clinical outcomes of the Visian ICL. J Refract Surg. 2011;27(7):473-481.

*American Refractive Surgery Council